BEZ235 plus everolimus (RAD001)
Phase 2Small molecule
BEZ235 plus everolimus (RAD001) is one of 36 small molecule programs targeting Respiratory tract infection. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Respiratory Tract Infection
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Tobrex
VViatris Specialty LLC
Approved
Merrem
BB. Braun Medical Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 3
Quietus
Merck & Co.Phase 2
Veklury
GileadPhase 2
Rapivab
BBioCryst Pharmaceuticals
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Pelubiprofen
Daewon Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRestorbio Inc.